The drug screening market is likely to expand its roots at a strong CAGR of 16.1% during the forecast period. The market holds a share of US$ 7.3 billion in 2023 while it is anticipated to cross a value of US$ 32.4 billion by 2033.
The research report on the drug screening market explains that more and more people indulging in drug consumption of different types along with the increasing number of rehab centers. Furthermore, the new government policies limit the use of drugs and drug trafficking are pushing the sales of drug screening solutions. Drug addicts promoting violence and drug abuse are pushing authorities to control the dissemination of drugs. The misuse and black marketing of prescribed drugs are fueling the demand for drug screening solutions. Furthermore, the development of drug screening products with higher efficiency and effectiveness gains traction for drug screening solutions. The higher penetration of recreational drugs among young people is fueling the demand for advanced drug screening solutions. Higher limitations on occupational drugs in non-Islamic countries are fueling the demand for drug screening solutions.
The drug screening market outlook states that the upcoming drug testing technology that is smart, efficient, and fast is likely to transform the market. Furthermore, the workspace discipline and extended drug screening prospects are fueling the demand for drug screening products.
| Attributes | Details |
|---|---|
| Drug Screening Market CAGR (2023 to 2033) | 16.1% |
| Drug Screening Market Size (2023) | US$ 7.3 billion |
| Drug Screening Market Size (2033) | US$ 32.4 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Short-term Growth: From 2017 to 2022, the global Drug Screening market registered a comparatively higher CAGR of 19.3%. The rise in regulatory approvals for the drug screening laboratory services market is ascribed to increased drug and alcohol usage and the implementation of rigorous legislation demanding alcohol and drug test. Bans on alcohol use in Islamic nations and limitations on an occupational drug tests in selected countries, on the other hand, may limit the market’s growth to some extent.
Mid-term Growth: Teenage illicit alcohol usage, rising road accidents owing to a drug overdose while driving, and prescription medication abuse are predicted to fuel market revenue growth. The growth between 2022 and 2028 is likely to be steady.
Long-term Growth: Covid-19 pandemic resulted in a worldwide restriction on the movement of people and led to the isolation of individuals in their own homes. This is the primary reason for the drop in demand for drug screening services as most of the workplaces were shut down, and healthcare resources were diverted to take care of covid-19 patients. However, apart from these factors limiting the growth, the market still thrives at a strong CAGR of 16.1% between 2023 and 2033.
The development of improved screening technology and growing awareness of the benefits of alcohol or drug screening are creating business opportunities.
Drug misuse and alcohol usage are on the rise all around the world. According to the World Drug Report 2021, 275 million persons aged 15–64, or one out of every 18 people in that age group, took drugs at least once in the preceding year (range: 175 million to 374 million).
Drug use problems were expected to affect 36.3 million individuals worldwide, accounting for over 13% of the global population. Drug use killed about half a million individuals in the same year, and drug use disorders resulted in the loss of 18 million years of a healthy life, primarily owing to opioids.
Similar increases in alcohol intake have been seen, with the resultant rise in the prevalence of impaired driving. Development of drug screening products and services on the road, boosting the total market growth.
Principal Consultant
Alcohol and drug tests in the workplace are considered a breach of employee privacy in certain nations, including Canada, Colombia, Argentina, Chile, and South Africa. In France, for example, pre-employment saliva drug testing is only done when doctors prescribe it.
Workplace alcohol and drug tests are illegal in Poland and the Czech Republic. In Canada, Eastern Canadian case laws allow alcohol and immunoassay drug tests only where occupational activities are fundamentally risky or when alcohol and drug testing is confined to a few specific circumstances.
Disruptions in the global supply chain, diminished demand, and client suspensions have all been experienced by companies in the drug screening sector. The test examines microscopic amounts of perspiration in the fingerprint to identify drugs and drug metabolites. This test might eventually replace urine, hair, and blood-based immunoassay drug test.
Although fingerprint-based swab drug test can help prevent the spread of COVID, it is non-invasive, portable, time-saving, and sanitary allows for social distancing, is user-friendly, and requires no unique sample collection or handling preparation.
This test is simple to administer whenever and wherever needed, making it ideal for workplace drug testing. To identify drugs and drug metabolites, a home drug test examines microscopic amounts of perspiration in the fingerprint. Workplaces, criminal justice, police enforcement, and drug recovery programs employ this test, which are offering opportunities to the market players.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Region | Absolute Market Growth |
|---|---|
| Chinese | US$ 8.8 billion |
| United Kingdom | US$ 1.0 billion |
| China | US$ 1.8 billion |
| Japan | US$ 1.4 billion |
| South Korea | US$ 837.2 million |
The Higher Misuse of Prescribed Drugs along with the Stringent Government Policies fuels the Regional Growth
| Region | Attributes |
|---|---|
| United States Market CAGR (2023 to 2033) | 15.8% |
| United States Market Absolute Doller Growth (US$ Mn/Bn) | US$ 8.8 billion |
According to the FMI market survey, the United States market thrives at a CAGR of 15.8% between 2023 and 2033 while it is expected to reach a value of US$ 11.5 billion by 2033. As there has been an increase in the consumption of illicit drugs by citizens of North American countries and the government increasingly investing in curbing drug abuse by establishing a drug screening laboratory services market, the region is expected to experience considerable growth in the years ahead. These factors make the United States the leading market in terms of market share and CAGR.
The growing burden of drunk and driving cases is also becoming a significant factor in law enforcement agencies growing demand for drug screening. Additionally, most of the primary critical players present in the North American drug screening market and adjoining areas have always favored the colossal market volume.
Increasing Cases of Drug Trafficking and Stringent Workspace Drug Norms flourishes the Sales of Drug Screening Solutions
| Region | Attributes |
|---|---|
| Chinese Market CAGR (2023 to 2033) | 15.4% |
| Chinese Market Absolute Doller Growth (US$ Mn/Bn) | US$ 1.8 billion |
Chinese drug screening market future trends appear optimistic, with opportunities in the workplace, criminal justice systems and law enforcement agencies, drug treatment centers, pain management centers, schools and colleges, hospitals, individual users, and drug testing laboratories. These factors make it the leading market in terms of market share and CAGR.
Fingerprint-based drug testing is a new concept that has gained traction and is one of the emerging trends in the Chinese drug screening market as an impact of COVID-19 on the overall drug screening market. Due to the risk of spreading the infection, the coronavirus has made it challenging to conduct drug testing in hospitals, labs, and other facilities. However, the Chinese market is still expected to hold US$ 2.3 billion in 2033 while thriving at a CAGR of 15.4% by 2033.
| Segment | Top Product and Service |
|---|---|
| Top Sub-segment | Rapid Testing Devices |
| CAGR (2017 to 2022) | 19.1% |
| CAGR (2023 to 2033) | 15.8% |
| Segment | Top End User |
|---|---|
| Top Sub-segment | Drug Testing Laboratories |
| CAGR (2017 to 2022) | 18.6% |
| CAGR (2023 to 2033) | 15.4% |
The product and services for the drug screening laboratory services market are categorized into drug screening products, analytical instruments, rapid testing devices, consumables, and drug screening services. Analytical Instruments are primarily breathalyzers, immunoassay analyzers, and chromatography instruments. Rapid testing devices have started gaining importance for drug monitoring programs and are predicted to overtake the global drug screening market in the coming years. This segment is further classified according to devices such as urine testing devices and oral fluid testing devices. The segment is expected to thrive at a CAGR of 15.8% by 2033.
Based on end-user type, drug testing laboratories are the top segment that thrives at a CAGR of 15.4% between 2023 and 2033. This is due to the lack of drug testing and screening equipment in private and government organizations. Despite the development of innovative drug screening methods, drug testing laboratories and hospitals will remain the significant consumers of products in the drug screening market. The segment thrived at a higher CAGR of 18.6% between 2017 and 2022.
Market players rely on the use of innovative technologies to derive efficiency in the drug screening kits and devices and get a hold of a better position in the drug screening market. In addition to this, the focus has also been on inorganic growth to get the benefit of collaboration and mutual growth. The key players in the market include Labcorp, Quest Diagnostics, Abbott Laboratories, and Orasure Technologies.
Recent Market Developments
North America is estimated to generate higher demand in 2023.
Asia Pacific is estimated to witness higher growth in 2023.
The drug screening laboratory services market is likely to thrive at a CAGR of 15.8% by 2033.
From 2017 to 2022, the global market exhibited a 19.3% CAGR.
China dominates the Asian market.
1. Executive Summary | Drug Screening Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Sample Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Sample Type, 2017 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sample Type, 2023 to 2033
5.3.1. Urine samples
5.3.2. Breath Samples
5.3.3. Oral Fluid Samples
5.3.4. Hair Samples
5.3.5. Other Samples
5.4. Y-o-Y Growth Trend Analysis By Sample Type, 2017 to 2022
5.5. Absolute $ Opportunity Analysis By Sample Type, 2023 to 2033
6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product and Service
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Product and Service, 2017 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product and Service, 2023 to 2033
6.3.1. Drug Screening
6.3.2. Analytical Instruments
6.3.3. Rapid Testing Devices
6.3.4. Consumables
6.3.5. Service
6.4. Y-o-Y Growth Trend Analysis By Product and Service, 2017 to 2022
6.5. Absolute $ Opportunity Analysis By Product and Service, 2023 to 2033
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2017 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2023 to 2033
7.3.1. Drug Testing Laboratories
7.3.2. Criminal Justice and Law Enforcement Agencies
7.3.3. Hospitals
7.3.4. Drug Treatment Centers
7.3.5. Individual Users
7.3.6. Pain Management Centers
7.3.7. Schools and Colleges
7.3.8. Workplaces
7.4. Y-o-Y Growth Trend Analysis By End User , 2017 to 2022
7.5. Absolute $ Opportunity Analysis By End User , 2023 to 2033
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The USA
9.2.1.2. Canada
9.2.2. By Sample Type
9.2.3. By Product and Service
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Sample Type
9.3.3. By Product and Service
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Sample Type
10.2.3. By Product and Service
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Sample Type
10.3.3. By Product and Service
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom (UK)
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Sample Type
11.2.3. By Product and Service
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Sample Type
11.3.3. By Product and Service
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Thailand
12.2.1.5. Singapore
12.2.1.6. Australia
12.2.1.7. Rest of Asia Pacific
12.2.2. By Sample Type
12.2.3. By Product and Service
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Sample Type
12.3.3. By Product and Service
12.3.4. By End User
12.4. Key Takeaways
13. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of Middle East and Africa
13.2.2. By Sample Type
13.2.3. By Product and Service
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Sample Type
13.3.3. By Product and Service
13.3.4. By End User
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Sample Type
14.1.2.2. By Product and Service
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Sample Type
14.2.2.2. By Product and Service
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Sample Type
14.3.2.2. By Product and Service
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Sample Type
14.4.2.2. By Product and Service
14.4.2.3. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Sample Type
14.5.2.2. By Product and Service
14.5.2.3. By End User
14.6. UK
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Sample Type
14.6.2.2. By Product and Service
14.6.2.3. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Sample Type
14.7.2.2. By Product and Service
14.7.2.3. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Sample Type
14.8.2.2. By Product and Service
14.8.2.3. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Sample Type
14.9.2.2. By Product and Service
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Sample Type
14.10.2.2. By Product and Service
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Sample Type
14.11.2.2. By Product and Service
14.11.2.3. By End User
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Sample Type
14.12.2.2. By Product and Service
14.12.2.3. By End User
14.13. Thailand
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Sample Type
14.13.2.2. By Product and Service
14.13.2.3. By End User
14.14. Singapore
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Sample Type
14.14.2.2. By Product and Service
14.14.2.3. By End User
14.15. Australia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Sample Type
14.15.2.2. By Product and Service
14.15.2.3. By End User
14.16. GCC Countries
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Sample Type
14.16.2.2. By Product and Service
14.16.2.3. By End User
14.17. South Africa
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Sample Type
14.17.2.2. By Product and Service
14.17.2.3. By End User
14.18. Israel
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Sample Type
14.18.2.2. By Product and Service
14.18.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Sample Type
15.3.3. By Product and Service
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Laboratory Corporation of America Holdings
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Hoffmann -La Roche Ltd
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. BioMerieux SA
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Express Diagnostics Int’l, Inc.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Bio-Rad Laboratories Inc.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Biomedical Diagnostics
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Danaher
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Synergy Health plc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Agilent Technologies
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Shimadzu Medical Pvt. Ltd.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.11. Alere Inc.
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.12. Premier Biotech, Inc.
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
16.1.13. Psychemedics Corporation
16.1.13.1. Overview
16.1.13.2. Product Portfolio
16.1.13.3. Profitability by Market Segments
16.1.13.4. Sales Footprint
16.1.13.5. Strategy Overview
16.1.13.5.1. Marketing Strategy
16.1.14. Siemens Healthineers Private Limited
16.1.14.1. Overview
16.1.14.2. Product Portfolio
16.1.14.3. Profitability by Market Segments
16.1.14.4. Sales Footprint
16.1.14.5. Strategy Overview
16.1.14.5.1. Marketing Strategy
16.1.15. American Bio Medica Corporation
16.1.15.1. Overview
16.1.15.2. Product Portfolio
16.1.15.3. Profitability by Market Segments
16.1.15.4. Sales Footprint
16.1.15.5. Strategy Overview
16.1.15.5.1. Marketing Strategy
16.1.16. Sciteck, Inc.
16.1.16.1. Overview
16.1.16.2. Product Portfolio
16.1.16.3. Profitability by Market Segments
16.1.16.4. Sales Footprint
16.1.16.5. Strategy Overview
16.1.16.5.1. Marketing Strategy
16.1.17. ACM Global Laboratories
16.1.17.1. Overview
16.1.17.2. Product Portfolio
16.1.17.3. Profitability by Market Segments
16.1.17.4. Sales Footprint
16.1.17.5. Strategy Overview
16.1.17.5.1. Marketing Strategy
16.1.18. CareHealth America
16.1.18.1. Overview
16.1.18.2. Product Portfolio
16.1.18.3. Profitability by Market Segments
16.1.18.4. Sales Footprint
16.1.18.5. Strategy Overview
16.1.18.5.1. Marketing Strategy
16.1.19. Clinical Reference Laboratory, Inc.
16.1.19.1. Overview
16.1.19.2. Product Portfolio
16.1.19.3. Profitability by Market Segments
16.1.19.4. Sales Footprint
16.1.19.5. Strategy Overview
16.1.19.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Drug Screening Market
